- Home
- PLYM vs ETNB Comparison
PLYM vs ETNB Comparison
Compare PLYM & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYM
- ETNB
- Stock Information
- Founded
- PLYM 2011
- ETNB 2018
- Country
- PLYM United States
- ETNB United States
- Employees
- PLYM N/A
- ETNB 70
- Industry
- PLYM Real Estate Investment Trusts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PLYM Real Estate
- ETNB Health Care
- Exchange
- PLYM Nasdaq
- ETNB Nasdaq
- Market Cap
- PLYM 817.0M
- ETNB 773.7M
- IPO Year
- PLYM 2017
- ETNB 2019
- Fundamental
- Price
- PLYM $17.11
- ETNB $6.58
- Analyst Decision
- PLYM Buy
- ETNB Buy
- Analyst Count
- PLYM 8
- ETNB 7
- Target Price
- PLYM $24.00
- ETNB $30.33
- AVG Volume (30 Days)
- PLYM 298.5K
- ETNB 1.3M
- Earning Date
- PLYM 02-26-2025
- ETNB 02-27-2025
- Dividend Yield
- PLYM 5.66%
- ETNB N/A
- EPS Growth
- PLYM N/A
- ETNB N/A
- EPS
- PLYM 0.01
- ETNB N/A
- Revenue
- PLYM $201,569,000.00
- ETNB N/A
- Revenue This Year
- PLYM N/A
- ETNB N/A
- Revenue Next Year
- PLYM $6.42
- ETNB N/A
- P/E Ratio
- PLYM $1,250.09
- ETNB N/A
- Revenue Growth
- PLYM 2.64
- ETNB N/A
- 52 Week Low
- PLYM $16.37
- ETNB $5.99
- 52 Week High
- PLYM $24.71
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- PLYM 36.24
- ETNB 37.36
- Support Level
- PLYM $16.62
- ETNB $5.99
- Resistance Level
- PLYM $17.34
- ETNB $6.65
- Average True Range (ATR)
- PLYM 0.43
- ETNB 0.39
- MACD
- PLYM 0.01
- ETNB -0.09
- Stochastic Oscillator
- PLYM 24.00
- ETNB 28.78
About PLYM Plymouth Industrial REIT Inc.
Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income primarily from the rental revenue through its properties.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).